{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:28:41Z","timestamp":1786728521740,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Accurate classification between non-clinically significant prostate cancer (non-csPCa) and clinically significant prostate cancer (csPCa) is essential for effective risk stratification and optimal management of prostate cancer. This study aimed to evaluate the consistency between preoperative and postoperative assessments of non-csPCa, and identify preoperative variables that can effectively predict the risk of csPCa. We analyzed data from 277 patients initially classified as non-csPCa after biopsy who underwent radical prostatectomy (RP) between August 2015 and January 2024. Univariate and multivariate logistic regression analyses were performed to identify predictors of csPCa. Receiver operating characteristic curves, calibration curves, and decision curve analyses were used to evaluate the performance of the nomogram model. Differences in biochemical recurrence rates between the non-csPCa group and csPCa group were analyzed using the log-rank test. Overall, 183 (66.1%) patients were reclassified as csPCa on the basis of postoperative pathology, with this group showing a higher incidence of biochemical recurrence versus non-csPCa (14 cases\n                    <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                    0;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.004). The following factors were independent predictors of csPCa: age, free prostate-specific antigen (fPSA)\/total prostate-specific antigen (tPSA) ratio, cumulative cancer length, clinical tumor stage, and PSA density. In addition, a nomogram was developed with good predictive accuracy (area under the curve: 0.782). The substantial inconsistency between biopsy and RP pathology findings in the classification of non-csPCa highlights the limitations of biopsy-only management. The developed nomogram predicting the risk of csPCa provides urologists with a valuable tool for improved risk stratification and PCa management.\n                  <\/jats:p>","DOI":"10.4103\/aja202547","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:00:57Z","timestamp":1751400057000},"page":"103-108","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["From non-clinically significant to clinically significant prostate cancer: identifying predictors of discrepancy from biopsy to radical prostatectomy"],"prefix":"10.4103","volume":"28","author":[{"given":"Yong-Qing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Ran","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ning","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"R1-20260122","first-page":"229","article-title":"Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s44178-024-00118-4","article-title":"CACA guidelines for holistic integrative management of prostate cancer","volume":"3","author":"Dai","year":"2024","journal-title":"Holist Integ Oncol"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1:screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/S0022-5347(01)62200-6","article-title":"Nonpalpable stage T1c prostate cancer:prediction of insignificant disease using free\/total prostate specific antigen levels and needle biopsy findings","volume":"160","author":"Epstein","year":"1998","journal-title":"J Urol"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000277591","article-title":"Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens:the role of prostate volume and the number of positive cores","volume":"84","author":"Ravent\u00f3s","year":"2010","journal-title":"Urol Int"},{"key":"R7-20260122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bju.12880","article-title":"Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?","volume":"116","author":"Chen","year":"2015","journal-title":"BJU Int"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/cncr.20586","article-title":"Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis","volume":"101","author":"Bastian","year":"2004","journal-title":"Cancer"},{"key":"R9-20260122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2008.03.049","article-title":"Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system:the lahey clinic medical center experience and an international meta-analysis","volume":"54","author":"Cohen","year":"2008","journal-title":"Eur Urol"},{"key":"R10-20260122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/pros.23936","article-title":"The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy:a contemporary analysis with grade groups","volume":"80","author":"Erdem","year":"2020","journal-title":"Prostate"},{"key":"R11-20260122","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eururo.2009.10.025","article-title":"The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy","volume":"58","author":"Lee","year":"2010","journal-title":"Eur Urol"},{"key":"R12-20260122","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights:prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT):a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1:2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","article-title":"Diagnostic value of systematic biopsy methods in the investigation of prostate cancer:a systematic review","volume":"175","author":"Eichler","year":"2006","journal-title":"J Urol"},{"key":"R16-20260122","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R18-20260122","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/pros.23905","article-title":"The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer","volume":"79","author":"Jang","year":"2019","journal-title":"Prostate"},{"key":"R19-20260122","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.juro.2016.11.079","article-title":"The impact of downgrading from biopsy Gleason 7 to prostatectomy Gleason 6 on biochemical recurrence and prostate cancer specific mortality","volume":"197","author":"Ham","year":"2017","journal-title":"J Urol"},{"key":"R20-20260122","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity \u2013United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"R23-20260122","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.juro.2013.09.034","article-title":"Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer","volume":"191","author":"Vellekoop","year":"2014","journal-title":"J Urol"},{"key":"R24-20260122","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1515\/cclm-2023-0008","article-title":"Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratio","volume":"61","author":"Ferraro","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"R25-20260122","doi-asserted-by":"crossref","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","article-title":"The use of prostate specific antigen density to predict clinically significant prostate cancer","volume":"10","author":"Yusim","year":"2020","journal-title":"Sci Rep"},{"key":"R26-20260122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1464-410X.2011.10681.x","article-title":"The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume","volume":"110","author":"Corcoran","year":"2012","journal-title":"BJU Int"},{"key":"R27-20260122","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer:a cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"key":"R28-20260122","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.23055","article-title":"A nomogram for predicting low-volume\/low-grade prostate cancer:a tool in selecting patients for active surveillance","volume":"110","author":"Nakanishi","year":"2007","journal-title":"Cancer"},{"key":"R29-20260122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.juro.2006.08.068","article-title":"Prediction of indolent prostate cancer:validation and updating of a prognostic nomogram","volume":"177","author":"Steyerberg","year":"2007","journal-title":"J Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:28:09Z","timestamp":1786724889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202547","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2025-02-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}